Proton-pump inhibitors do not influence serum magnesium levels in renal transplant recipients.
This study is the first to analyze the potential impact of PPIs on magnesium level in a large, representative cohort of RTR patients. Our results suggest that PPIs may be used without particular fear of favoring hypomagnesemia-related side effects in RTRs, an important finding in a population at high risk of hypomagnesemia.
PMID: 24816563 [PubMed - as supplied by publisher] (Source: Journal of Nephrology)